Resources from the same session
KRASG12C inhibitors: expanding outcomes from clinical studies to real-world patient populations
Presenter: Melissa Johnson
Session: Amgen - Innovation in lung cancer treatment: unlocking the potential of precision medicine
Resources:
Webcast
Engaging T cells in SCLC: the DLL3-targeted approach
Presenter: Anne-Marie Dingemans
Session: Amgen - Innovation in lung cancer treatment: unlocking the potential of precision medicine
Resources:
Webcast
Expert perspectives: optimising care for patients receiving DLL3 T-cell engagers
Presenter: Maurice Pérol
Session: Amgen - Innovation in lung cancer treatment: unlocking the potential of precision medicine
Resources:
Webcast
Advancing lung cancer treatment: emerging targets and novel therapies
Presenter: Ernest Nadal
Session: Amgen - Innovation in lung cancer treatment: unlocking the potential of precision medicine
Resources:
Webcast
Panel discussion and Q&A
Presenter: Ernest Nadal, Melissa Johnson, Anne-Marie Dingemans, Maurice Pérol
Session: Amgen - Innovation in lung cancer treatment: unlocking the potential of precision medicine
Resources:
Webcast
Summary and close
Presenter: Ernest Nadal
Session: Amgen - Innovation in lung cancer treatment: unlocking the potential of precision medicine
Resources:
Webcast